Time to rethink haemoglobin threshold guidelines in sickle cell disease

Alleviating anaemia in patients with sickle cell disease (SCD) is crucial in managing acute complications, mitigating end‐organ damage and preventing early mortality. Some disease‐modifying and curative therapies have increased haemoglobin (Hb) levels to exceed 100 g/l, a threshold above which compl...

Descripción completa

Detalles Bibliográficos
Autores principales: Ballas, Samir K., Kuypers, Frans A., Gordeuk, Victor R., Hankins, Jane S., Thompson, Alexis A., Vichinsky, Elliott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Wider Perspectives
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9292304/
https://www.ncbi.nlm.nih.gov/pubmed/34131897
http://dx.doi.org/10.1111/bjh.17578
Descripción
Sumario:Alleviating anaemia in patients with sickle cell disease (SCD) is crucial in managing acute complications, mitigating end‐organ damage and preventing early mortality. Some disease‐modifying and curative therapies have increased haemoglobin (Hb) levels to exceed 100 g/l, a threshold above which complications from red blood cell (RBC) transfusions have occurred, raising concern about whole‐blood viscosity‐related complications with these therapies. Here we discuss the rationale behind this limit, the effect of viscosity on blood flow and the applicability of this Hb threshold to therapies for SCD beyond RBC transfusions.

Ejemplares similares